Ionis Pharmaceuticals, Inc. (IONS) Earnings Call Transcripts

Ionis Pharmaceuticals, Inc.'s Latest Earnings Call - June 10, 2026

Ionis Pharmaceuticals reported its Q2 2026 earnings, highlighting significant strategic advancements and upcoming catalysts that could impact the stock. The company is transitioning to a fully integrated commercial biotech, with recent launches of TRYNGOLZA and DAWNZERA. Revenue guidance for TRYNGOLZA is set at $100-$110 million for 2026, factoring in a price reduction to $40,000. Management emphasized upcoming PDUFA dates and potential multibillion-dollar opportunities in severe hypertriglyceridemia and neurology, with a focus on achieving cash flow breakeven by 2028.

Reported metrics

Guidance from management

Ionis maintained its guidance for TRYNGOLZA revenue at $100-$110 million for 2026 and aims for cash flow breakeven by 2028. The company expects continued revenue growth driven by new product launches.

What analysts pressed on

Analysts questioned the competitive landscape, particularly regarding TRYNGOLZA's pricing and market share against competitors. Concerns were also raised about the potential impact of competitor data on Ionis's market position.

Main topics on the call

• Transition to Commercial Biotech — Ionis is evolving from an R&D organization to a fully integrated commercial biotech. 'We've achieved this... launched our first 2 products, wholly owned products, TRYNGOLZA for familial chylomicronemia syndrome.'
• TRYNGOLZA Launch and Pricing Strategy — TRYNGOLZA's launch for severe hypertriglyceridemia is a 'multibillion-dollar product opportunity.' The WACC price was set at $40,000 to ensure payer access and align with 2027 budget cycles.
• Upcoming Catalysts and Pipeline Progress — Key upcoming events include the PDUFA date for TRYNGOLZA and the launch of Zilganersen. 'Our objective is to be cash flow breakeven in 2028 with revenue growth.'
• Neurology Pipeline and Angelman Program — Ionis is confident in its Angelman program, expecting Phase III data next year. 'Confidence a proven platform... expressive communication as our primary endpoint.'

Read the full Ionis Pharmaceuticals, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 156 Ionis Pharmaceuticals, Inc. earnings call transcripts on record, spanning January 15, 2020 to July 29, 2026. Based on this history, Ionis Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated July 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IONS

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

156

First call

January 15, 2020

Most recent

July 29, 2026

Reporting cadence

quarterly